European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer's treatment lecanemab a few months after rejecting ...
Eisai wins over European regulators on Alzheimer’s drug Leqembi
A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.
Santé log8m
Ascendis Pharma Reports Third Quarter 2024 Financial Results
For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) compared to a net loss of €162.2 million, or €2.88 per share (basic and ...
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
HITN-TV Partners with South Florida PBS to Bring "From Fear to Hope: The HIV & AIDS Journey" to Hispanic Audiences Nationwide
TV, the nation's leading Spanish-language public broadcaster, is proud to announce a partnership with South Florida PBS to ...
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on ...